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ABO blood group and more recently high von Willebrand
factor (VWF) and factor (F)VIII levels have been associated
with thrombotic disease. An excess of non-O blood group has
long been recognized in patients with ischemic heart disease [1]
and venous thrombosis [2]. In 1995, we demonstrated that non-
O blood group, high VWF levels and high FVIII levels all
increased the risk of deep vein thrombosis [3]. In multivariate
analysis only FVIII remained a risk factor, whereas the
thrombosis risk associated with VWF and ABO blood group
largely disappeared. Since then, several other studies have
identiﬁed high FVIII levels as a risk factor for venous
thrombosis [4–7].
Usually blood group phenotypes are used to study the
associationbetweenbloodgroupandvenous thrombosis.Blood
group genotypes may be more informative since genotypes can
distinguish between heterozygous and homozygous carriers of
A, B and O alleles and between A1 and A2 alleles. Therefore we
studied the effect ofABOgenotype on thrombosis risk in a large
population-based case–control study of venous thrombosis
(Leiden Thrombophilia Study, LETS). This study, which
included 474 patients and 474 control subjects, has been
previously described [3]. For the present study DNA was
available for 471 patients and 471 control subjects.
Blood was collected into 0.1 volume 0.106 mol L)1 tri-
sodium citrate. Plasma was prepared by centrifugation for
10 min at 2000 · g at room temperature and stored at )70 C.
FVIII coagulant activity (FVIII:C), FVIII:Ag, VWF:Ag and
blood group phenotype were measured as previously reported
[3–5].
High-molecular-weight DNA was isolated from leukocytes
and stored at 4 C. Polymerase chain reaction (PCR) was
designed to amplify exons 6 and 7 of the ABO blood group
gene in two separate reactions. The sequences of the primers
have been described previously [8]. The ampliﬁed DNA
fragments corresponding to exons 6 and 7 were digested with
Acc65I (MBI Fermentas) or MspI (MBI Fermentas), respect-
ively, in two separate reactions and separated by electrophor-
esis on 3.5% agarose gels. With this method we discriminated
A1, A2, B, O1 and O2 alleles. There was 99% agreement
between ABO blood group phenotype and genotypes in all
patients and controls.
Table 1 (upper part) shows the frequency of the ABO blood
group genotypes in patients and controls. Odds ratios (OR)
were calculated as estimates of the relative risk by anunmatched
method. Ninety-ﬁve percent conﬁdence intervals were assessed
according to Woolf [9]. All non-OO genotypes except A2
homozygotes or A2–O combinations, i.e. A2O1/A2O2/A2A2,
were associated with an increased thrombosis risk when
compared with OO genotypes. This reinforces the concept that
blood group exerts its thrombotic risk largely via FVIII levels,
since A2O/A2A2 genotypes correspond to the lowest FVIII
levels among non-OO genotypes (data not shown). Adjustment
for age and sex did not alter the risk estimates.
Because blood group is known to affect plasma levels of
VWF and FVIII and because VWF and FVIII levels inﬂuence
thrombosis risk, we adjusted the thrombosis risk associated
Table 1 Thrombosis risk for ABO blood group genotypes
Genotypes
No. of
patients (%)
n ¼ 471
No. of
controls (%)
n ¼ 471 OR 95% CI
O1O1/O1O2 137 (29.1) 202 (42.9) 1*
Non-OO 334 (70.9) 269 (57.1) 1.8 (1.4-2.4)
A1A1 29 (6.2) 20 (4.2) 2.1 (1.2-3.9)
A1A2 19 (4.0) 15 (3.2) 1.9 (0.9-3.8)
A1O1/A1O2 177 (37.6) 130 (27.6) 2.0 (1.5-2.7)
A2O1/A2O2/A2A2 34 (7.2) 41 (8.7) 1.2 (0.7-2.0)
BB/BO1/BO2 52 (11.0) 47 (10.0) 1.6 (1.0-2.6)
A1B/A2B 23 (4.9) 16 (3.4) 2.1 (1.1-4.1)
OO and FVL (–) 113 (24.0) 193 (41.0) 1*
OO and FVL (+) 24 (5.1) 9 (1.9) 4.6 (2.0-10.1)
Non-OO and FVL (–) 266 (56.5) 264 (56.0) 1.7 (1.3-2.3)
Non-OO and FVL (+) 68 (14.4) 5 (1.1) 23.2 (9.1-59.3)
Number of subjects composing the genotypes with lower frequency:
patients, A1O2 (n ¼ 3), A2A2 (n ¼ 2), BB (n ¼ 4), BO2 (n ¼ 3), A2B
(n ¼ 4), O1O2 (n ¼ 3). A2O2 genotype was not observed among
patients; controls, A1O2 (n ¼ 4), A2O2 (n ¼ 1), A2A2 (n ¼ 1), BB (n ¼
1), BO2 (n ¼ 1), A2B (n ¼ 3), O1O2 (n ¼ 11). FVL, Heterozygous
(1691AG) and homozygous (1691AA). *Reference category.
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with blood group non-OO genotypes for VWF and FVIII in a
logistic regression model (see also Koster et al. [3]). The aim of
this analysis was to assess whether a blood group effect on risk
was present that did not act via levels of VWF and FVIII.
VWF:Ag and FVIII:C had been measured in 301 patients and
299 controls in whom ABO genotypes were also determined.
The crude thrombosis risk for non-OO carriers compared with
OO carriers [OR 2.0; 95% conﬁdence interval (CI) 1.4-2.8]
decreased after adjustment for FVIII:C only (OR 1.5; 95% CI
1.0-2.1), for VWF:Ag only (OR 1.6; 95% CI 1.1-2.3), or for
both FVIII:C and VWF:Ag (OR 1.4; 95%CI 1.0-2.1). For this
analysis we stratiﬁed FVIII:C and VWF:Ag levels into
approximate quartiles. Similar results were obtained when
FVIII:Ag was used instead of FVIII:C and when FVIII:C and
VWF:Ag were entered into the model as continuous variables.
So, even after extensive adjustment for VWF and FVIII levels,
some risk-enhancing effect of blood group remained present.
One explanation is that, due tomeasurement error, wewere not
able to adjust completely for VWF and FVIII levels. The other
explanation is that there is an additional effect of blood group
on thrombosis risk. It is unlikely that this effect also acts via
VWF (e.g. via its effect on platelet adhesion and aggregation),
since adjustment for FVIII only and for FVIII and VWF
together reduced the risk associated with non-OO blood group
to the same extent.
Among the 471 patients, 92 (19.5%) carried factor (F)V
Leiden compared with 14 (3.0%) of the 471 controls, yielding
an OR for venous thrombosis of 7.9 (95%CI 4.4, 14.1) [10]. In
carriers of FVLeiden, non-OO genotypes were present in 68/92
(74%) patients vs. 5/14 (36%) controls. Table 1 (lower part)
shows separate and combined effects of ABO blood group and
FV Leiden on thrombosis risk. The risk of the combination of
non-OO blood group genotypes and FV Leiden, compared
with subjects with OO genotypes and without FV Leiden was
23-fold increased. This is higher than expected on the basis of
the effects of non-OO genotype (OR 1.7) and FV Leiden (OR
4.6) separately. Adjustment for age and sex did not inﬂuence
these risk estimates. Similar results were obtained when we
limited the analysis to carriers of the risk-enhancing A1 and B
alleles (because A2O/A2A2 genotypes were not associated with
risk). This ﬁnding extends previous observations [11,12]. In one
study, among 28 subjects with FV Leiden and venous
thrombosis, 96% possessed non-O blood group, while in a
second study [12] among carriers of FV Leiden the thrombosis
risk for subjects with non-O blood group was increased 4-fold
compared with those with O blood group. Also, our previous
observation that in selected thrombophilic families with FV
Leiden elevated FVIII levels (¼ 150 IU dL)1) contribute
substantially to the incidence rate of thrombosis in FV Leiden
carriers, explains the higher frequency of non-O blood group in
these families [13].
The mechanism by which non-O blood group contributes to
the thrombosis risk in carriers of the FV Leiden mutation is
mainly explained by its effect on FVIII levels. High FVIII levels
are associated with a decreased responsiveness to activated
protein C (APC) in the absence of FV Leiden [14]. In FV
Leiden carriers this small additional effect on the APC
sensitivity might result in an exponential increase in thrombosis
risk. In a similar way the small additional effect of oral
contraceptive use on the APC sensitivity ratio in FV Leiden
carriers results in amore than additive effect on thrombosis risk
[15]. There is also evidence that FV Leiden is a defective
cofactor in the inactivation of FVIIIa by APC [16], in which
case the combination of poor inactivation of FVIIIa and high
FVIII levels associated with non-O blood groupmight result in
a more pronounced reduction in the sensitivity for APC.
Our data indicate that carriers of blood group alleles A1 and
B have a 2-fold increased risk of a ﬁrst deep vein thrombosis
and that the non-OO genotypes strongly inﬂuence the risk of
thrombosis in FV Leiden carriers. Therefore information on
blood group genotype may play a role in the management of
thrombophilia patients, especially when they are carriers of FV
Leiden.
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Deep vein thrombosis (DVT) and pulmonary embolism (PE)
are common and clinically important complications of major
surgery. Without thromboprophylaxis, the risk of venograph-
ically detected DVT ranges from 50 to 58% of patients
following total hip and 57 to 74% following total knee
replacement surgery [1]. At present it is standard practise to use
perioperative thromboprophylaxis. In the last decades, there
has been a major shift from the full clinical approaches to day-
care surgery. In North America two-thirds of all surgery is
performed in day-care practice [2] compared with about 30%
in the Netherlands [3]. There are few studies describing the
incidence of postoperative venous thromboembolism (VTE)
after day-care surgery. Arthroscopy of the knee seems to carry
a relatively high risk of VTE in this setting [4,5]. In contrast to
full clinical surgical approaches, inmany institutions patients in
day-care surgery do not receive perioperative thromboproph-
ylaxis [6]. Until now it seems there has been no consensus
regarding a thromboprophylactic regime. In the Netherlands,
about 60% of all patients undergoing knee arthroscopy in a
day-care setting receive a single injection of low-molecular-
weight heparin (LMWH) postoperatively, while the remainder
do not receive any form of thromboprophylaxis [6]. The
potential for VTE increases with the duration and extent of the
surgery performed [7]. Hence, the main rationale not to use
thromboprophylaxis in day-care surgery is the idea that the
operations performed in this setting are less invasive, leading to
an earlier resumption of normal physical activities. At present,
however, surprisingly little is known about postoperative
mobilization after day-care surgery. The aim of this study
was to assess the incidence of symptomatic VTE and the
duration of immobilization after arthroscopy of the knee in a
day-care setting.
A questionnaire was developed focusing on postoperative
symptomatic VTE and duration of immobilization, within a
follow-up of 6 weeks, after arthroscopy of the knee in a day-
care setting. All consecutive patients who underwent an
arthroscopy of the knee in day-care in the Academic Medical
Center (AMC) in Amsterdam during 1 year were sent a
questionnaire. Surgeons at the AMC operated a large part of
their patients also in the Jan van Gooyen clinic (JvG) in
Amsterdam. If no reply was received, a second package was
mailed. To the remaining non-responders the general practi-
tioner (GP) was sent a questionnaire. All data following
arthroscopy in day-care were analyzed for the AMC and the
JvG separately.
Categorical data and dichotomous variables were summar-
ized as percentages when applicable. Continuous variables were
compared using Student’s t-test or in case of an abnormal
distribution the Mann–Whitney U-test. Categorical data were
compared with cross tabulation (v2 or Fischer’s exact test).
In the year 2000, 270 patients underwent a unilateral
arthroscopy of the knee, 88 in the AMC and 182 in the JvG.
Replies were received from 173 patients (64%). Of the
remaining 97, the GP returned 74 questionnaires (76%). The
overall response rate was therefore 91% (247 out of 270), 93%
and 91%, respectively, for the AMC and JvG. The patients’
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